A5106721347- Amyloidosis: Diagnosis, Treatment, Outcomes
- Multiple Myeloma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Parathyroid Disorders and Treatments
- Total Knee Arthroplasty Outcomes
- Orthopedic Infections and Treatments
- Orthopaedic implants and arthroplasty
- Sarcoidosis and Beryllium Toxicity Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Renal Diseases and Glomerulopathies
- Alzheimer's disease research and treatments
- Renal and Vascular Pathologies
- Liver Disease Diagnosis and Treatment
- Hematological disorders and diagnostics
- Pancreatitis Pathology and Treatment
- Bone health and treatments
- Cell death mechanisms and regulation
- Protein Degradation and Inhibitors
- Chronic Myeloid Leukemia Treatments
- Medical Imaging and Pathology Studies
- Cardiac tumors and thrombi
- Cardiac Imaging and Diagnostics
- Cardiovascular Function and Risk Factors
- Acute Myeloid Leukemia Research
- Inflammatory Myopathies and Dermatomyositis
Mayo Clinic in Arizona
2018-2025
Mayo Clinic
2021-2024
WinnMed
2024
Two-stage exchange arthroplasty with a high-dose antibiotic-loaded bone cement (ALBC) spacer and intravenous or oral antibiotics is the most common method of managing periprosthetic joint infection (PJI) after total knee (TKA). However, little known about contemporary incidence, risk factors, outcomes acute kidney injuries (AKIs) in this cohort.We identified 424 patients who had been treated 455 ALBC spacers resection PJI following primary TKA from 2000 to 2017. The mean age at was 67 years,...
e19531 Background: Effective treatment and elimination of clonal plasma cells (PC) in multiple myeloma (MM) are typically associated with recovery polyclonal (normal) (PPC). Studies suggest that robust PPC is better outcomes. However, it unclear if this remains valid the context monoclonal antibodies, such as Daratumumab, selectively target cells, turn, may adversely impact recovery. Methods: We identified patients MM who underwent MRD testing using Euroflow method at 6-12 months after...
7541 Background: Multiple myeloma (MM) is characterized by recurrent cytogenetic abnormalities, including translocations involving the immunoglobulin heavy chain locus on chromosome 14 and trisomies, which are considered primary clonal. Throughout disease progression, MM cells may acquire additional include 1 abnormalities (gain or amplification of 1q deletion 1p) 17 (del 17p monosomy 17p). All these factors high-risk markers that predict below-average outcomes. While outcomes related to...